Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired Specific assets from Mithra Recherche Et Développement Sa on June 11, 2024. Mithra Pharmaceuticals sells all shares held in Neuralis SA and Estetra SRL as well as specific assets of Mithra R&D SA to Gedeon Richter for an aggregate price of ?175 million. The amount received, after deduction of financial debts, will be used to repay certain amounts to Mithra?s creditors in the order of their legal privilege. As a result, this transaction does not create any value for the shareholders of Mithra Pharmaceuticals SA. This transfer includes the related intellectual property rights and current contracts, as well as ESTELLE (already marketed) and DONESTA (in development). Gedeon Richter will be responsible for submitting the DONESTA filing to the agencies and for liaising with the regulatory agencies for the purposes of obtaining marketing authorization and then marketing the product via existing and future contracts. From an employment point of view, all 49 members of the personnel engaged by the transferred entities will be able to pursue their activities with Gedeon Richter. In addition, 17 other people of Mithra Pharmaceuticals SA have also been offered to join the transferred entities and thus work for Gedeon Richter.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of Specific assets from Mithra Recherche Et Développement Sa on June 11, 2024.